Abstract: The present invention relates to a novel chimeric antigen receptor comprising a CD99L2 region, which is known to play a key role in cell adhesion and migration, as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99L2-based CAR-T cells exhibit enhanced T-cell activity and tumor treatment efficiency compared to conventional CAR-T cells, and thus can be useful in immune cell therapy for the treatment of cancer.
Type:
Application
Filed:
August 26, 2022
Publication date:
January 30, 2025
Applicant:
TICAROS CO., LTD
Inventors:
Kyungho CHOI, Eun-Young CHOI, Giri NAM, Hanna CHANG, Hyeonji LIM, Hye-Ran YEON, Hyung-Bae PARK
Abstract: The present invention relates to a novel chimeric antigen receptor comprising a CD99 region which participates in immune synapse stabilization as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99-based CAR-T cells are capable of forming very stable immune synapses with tumor cells compared to conventional backbone-based CAR-T cells and can exhibit improved tumor therapeutic efficiency, so they can be useful for immune cell therapy for the treatment of cancer.
Abstract: The present invention relates to a novel chimeric antigen receptor comprising a CD99 region which participates in immune synapse stabilization as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99-based CAR-T cells are capable of forming very stable immune synapses with tumor cells compared to conventional backbone-based CAR-T cells and can exhibit improved tumor therapeutic efficiency, so they can be useful for immune cell therapy for the treatment of cancer.
© 2025 Justia
